^
    Apply
    Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma (NCT06008106)
    Phase 3
    Shanghai Kechow Pharma, Inc.
    Not yet recruiting
    Last update posted :
    08/23/2023
    Initiation :
    09/22/2023
    Primary completion :
    09/22/2027
    Completion :
    09/22/2027
    NRAS
    |
    NRAS mutation
    |
    cisplatin • carboplatin • paclitaxel • temozolomide • dacarbazine • tunlametinib (HL-085)
    Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (NCT06008119)
    Phase 3
    Shanghai Kechow Pharma, Inc.
    Not yet recruiting
    Last update posted :
    08/23/2023
    Initiation :
    11/24/2023
    Primary completion :
    12/24/2026
    Completion :
    12/24/2026
    BRAF
    |
    BRAF V600E • BRAF V600
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Zelboraf (vemurafenib) • tunlametinib (HL-085)
    Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study (NCT05900219)
    Phase 2
    Shanghai Kechow Pharma, Inc.
    Not yet recruiting
    Last update posted :
    06/12/2023
    Initiation :
    09/24/2023
    Primary completion :
    09/24/2025
    Completion :
    09/24/2025
    PD-L1 • BRAF
    |
    BRAF V600E • BRAF V600
    |
    Zelboraf (vemurafenib) • tunlametinib (HL-085)
    A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation (NCT03781219)
    Phase 1
    Shanghai Kechow Pharma, Inc.
    Recruiting
    Last update posted :
    05/31/2023
    Initiation :
    07/01/2018
    Primary completion :
    12/01/2023
    Completion :
    12/01/2023
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Zelboraf (vemurafenib) • tunlametinib (HL-085)
    Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) (NCT05233332)
    Phase 2
    Shanghai Kechow Pharma, Inc.
    Recruiting
    Last update posted :
    05/31/2023
    Initiation :
    02/24/2022
    Primary completion :
    01/20/2024
    Completion :
    07/20/2024
    BRAF
    |
    Zelboraf (vemurafenib) • tunlametinib (HL-085)
    HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation (NCT05263453)
    Phase 2
    Shanghai Kechow Pharma, Inc.
    Recruiting
    Last update posted :
    05/31/2023
    Initiation :
    09/06/2021
    Primary completion :
    09/30/2024
    Completion :
    12/31/2024
    BRAF
    |
    BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K
    |
    Zelboraf (vemurafenib) • tunlametinib (HL-085)
    HL-085 in NRAS-mutated Advanced Melanoma (NCT05217303)
    Phase 2
    Shanghai Kechow Pharma, Inc.
    Completed
    Last update posted :
    05/31/2023
    Initiation :
    11/02/2020
    Primary completion :
    02/19/2023
    Completion :
    02/20/2023
    NRAS
    |
    NRAS mutation
    |
    tunlametinib (HL-085)
    HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (NCT05331105)
    Phase 2
    Shanghai Kechow Pharma, Inc.
    Recruiting
    Last update posted :
    05/31/2023
    Initiation :
    10/18/2021
    Primary completion :
    10/30/2025
    Completion :
    10/31/2028
    NF1
    |
    NF1 mutation
    |
    tunlametinib (HL-085)
    Study of HL-085 in NRAS Mutant Advanced Melanoma (NCT03973151)
    Phase 1/2
    Shanghai Kechow Pharma, Inc.
    Completed
    Last update posted :
    05/31/2023
    Initiation :
    09/01/2017
    Primary completion :
    01/18/2021
    Completion :
    01/18/2021
    NRAS
    |
    NRAS mutation
    |
    tunlametinib (HL-085)